VEGFA and neoplasm: Since the opening of this research window, the preclinical and clinical data started accumulating in a logarithmic manner, with a clear intention of inhibiting the tumor angiogenesis.2 Till date, 10 anti-angiogenic agents have been approved by the US Food and Drug Administration: bevacizumab and ziv-aflibercept as anti-vascular endothelial growth factor (VEGF) agents, whereas sorafenib, sunitinib, pazopanib, axitinib, cabozantinib and regorafenib are approved as small-molecule RTK (receptor tyrosine kinase) inhibitors.3